NCT03990103 is a Phase 2 clinical trial of S1 in Metastatic Gastric Adenocarcinoma, sponsored by China Medical University, China.

Who is sponsoring NCT03990103?

NCT03990103 is sponsored by China Medical University, China.

What drugs are being tested in NCT03990103?

Interventions in NCT03990103: S1, Paclitaxel, Bevacizumab, Oxaliplatin.

What condition does NCT03990103 study?

NCT03990103 studies Metastatic Gastric Adenocarcinoma.

Is NCT03990103 still recruiting?

NCT03990103 is currently status unknown. Last updated 19 June 2019.

Last reviewed 2019-06-19 · How we verify

NCT03990103

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites

Status unknown Phase 2 Last updated 19 June 2019

What this trial tests

Phase 2 trial testing S1 in Metastatic Gastric Adenocarcinoma in 66 participants. Status unknown.

Timeline

1 November 2017

Primary endpoint
30 April 2021

30 April 2022

Quick facts

Lead sponsor	China Medical University, China
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	66
Start date	1 November 2017
Primary completion	30 April 2021
Estimated completion	30 April 2022
Sites	1 location across China

Drugs / interventions tested

S1
Paclitaxel — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Oxaliplatin (Oxaliplatin) — full drug profile →

Conditions studied

Metastatic Gastric Adenocarcinoma — all drugs for Metastatic Gastric Adenocarcinoma →

Sponsor

China Medical University, China

Who can join

Adults 18 to 70, any sex, with Metastatic Gastric Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the efficacy of S1 plus paclitaxel (intravenous injection \& intraperitoneal injection) plus bevacizumab (intraperitoneal injection) vs. S1 plus oxaliplatin intravenous injection as first-line treatment in gastric or gastroesophageal junctional adenocarcinoma with malignant ascites.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies.
Guchelaar NAD, Noordman BJ, Koolen SLW, Mostert B, et al · · 2023 · cited 28× · PMID 36633826 · DOI 10.1007/s40265-022-01828-7
Molecular pathogenesis and emerging targets of gastric adenocarcinoma.
Ivey A, Pratt H, Boone BA. · · 2022 · cited 9× · PMID 35481910 · DOI 10.1002/jso.26874

Verify or expand the search:

Other trials of S1

Trials testing the same drug.

NCT07038629 — Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC · Phase 2 · recruiting
NCT05872685 — Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS- · Phase 2 · recruiting
NCT05970627 — Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastri · Phase 2 · not yet recruiting
NCT05729646 — Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma · Phase 2 · recruiting
NCT05822453 — Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma · Phase 2 · not yet recruiting

Other recruiting trials for Metastatic Gastric Adenocarcinoma

Currently open trials in the same condition.

NCT06675136 — Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal · Phase 1 · recruiting
NCT07043400 — A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy · Phase 3 · recruiting
NCT06203600 — Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · Phase 2, PHASE3 · recruiting
NCT06324357 — Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Te · Phase 1, PHASE2 · recruiting
NCT05927857 — Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . · Phase 1, PHASE2 · recruiting

Other China Medical University, China trials

Trials by the same sponsor.

NCT07519837 — Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics · NA · recruiting
NCT07388875 — Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC · Phase 2 · not yet recruiting
NCT07376499 — Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum a · Phase 2 · not yet recruiting
NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03990103 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China Medical University, China
Last refreshed: 19 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03990103.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing